StrongDM | $34,000,000 | (May 3, 2024)
Volta Circuit | $4,100,000 | (May 3, 2024)
Bricklayer AI | $2,500,000 | (May 3, 2024)
Salubris Biotherapeutics
United States
- Gaithersburg, MD
- 23/04/2024
- Unknown
- $35,000,000
SalubrisBio was founded in August 2016 as a subsidiary of the China-based pharmaceutical company Salubris Pharmaceuticals Co. Ltd. (www.salubris.com). SalubrisBio is an innovation-focused biotech with pioneering research and development programs. Headquartered in Gaithersburg, Maryland, SalubrisBio represents and reflects Salubris Pharmaceuticals’ commitment to innovation and expansion into the global market. SalubrisBio focuses exclusively on the discovery and global development of novel, biologic therapeutics.
Salubris Pharmaceuticals is a publicly-traded company [002294:CH], founded in 1998, which has grown to achieve sales of >$750M USD in 2016. Salubris Pharmaceuticals is a fully-integrated drug development company. Headquartered in Shenzhen, China, Salubris Pharmaceuticals has over 3,000 employees working across R&D, regulatory, marketing and sales. Its marketed products include small molecule drugs in the cardiovascular, anti-allergy and anti-infective therapeutic areas.
GeneKey Biotech Ltd. Co. (www.genekeybio.com), based in Chengdu, China, is the China-based biologics subsidiary of Salubris Pharmaceuticals. GeneKey Biotech has a robust portfolio of biosimilar and novel large molecule therapeutics in development in China. SalubrisBio maintains close cross-functional collaborations with GeneKey Biotech, leveraging resources including the expertise of >150 research scientists and large-scale manufacturing of up to 2000L scale.
- Industry Biotechnology Research
- Website https://www.salubrisbio.com/
- LinkedIn https://www.linkedin.com/company/salubris-biotherapeutics/
Related People
Samuel MurphyFounder
United States -
Cambridge, Massachusetts
Catalyzing global growth and technological innovation through innovative R&D focused on complex biologics and a broad business development mandate spanning licensing, acquisitions and strategic investments.
Focus on cardiometabolic disease and oncology. Initiating first ever clinical trial of a bi-specific antibody in a cardiovascular indication (heart failure - https://clinicaltrials.gov/ct2/show/NCT04210375).
Livara Health | $15,000,000 | (May 3, 2024)
Altruist | $169,000,000 | (May 3, 2024)
Symbe | $1,505,700 | (May 3, 2024)
GroundGame.Health | $17,000,000 | (May 3, 2024)
APEX(ISRAEL) | $7,000,000 | (May 3, 2024)
Karius | $100,000,000 | (May 3, 2024)
Mimic | $27,000,000 | (May 3, 2024)
Maia Farms | $2,300,000 | (May 3, 2024)
Tuza (formerly Statement) | $5,020,220 | (May 3, 2024)